ASCO

Results from KEYNOTE-021 Cohort D: a Phase 1 Study of Pembrolizumab plus Ipilimumab as Second-line Therapy for Advanced NSCLC

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

Clinical Correlation and Frequency of PD-L1 Expression in EGFR-Mutant and ALK-Rearranged NSCLC

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

Results from POPLAR: Efficacy, Safety, and Predictive Biomarker Results From a Randomized Phase 2 Study Comparing MPDL3280A vs Docetaxel in NSCLC

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

Checkmate 017: A Phase 3 Study of Nivolumab vs Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell NSCLC

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

Final Overall Survival Results of the Phase 3 PROCLAIM Trial

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

Necitumumab in Metastatic Squamous NSCLC: Establishing a Value-Based Cost

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

Phase 1-1B Trial of Tivantinib in Combination with Carboplatin and Pemetrexed as First-Line Treatment in Patients with Advanced Nonsquamous NSCLC or Malignant Pleural Mesothelioma

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

A Phase 3B/4 Safety Trial of Nivolumab (NIVO) in Patients with Advanced or Metastatic NSCLC

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

Phase 3 Trial (Checkmate 057) of Nivolumab (NIVO) Versus Docetaxel (DOC) In Advanced Non Squamous Cell (Non-SQ) NSCLC

ASCO 2015 - Lung Cancer, ASCO

Conference Correspondent

Combination of BRAF and MEK Inhibitors Improves Survival in Patients with Advanced Melanoma

By Phoebe Starr

ASCO 2014 Highlights, ASCO

October 2014, Vol 5 , No 8

Madrid, Spain—Combination therapy with a BRAF inhibitor and a MEK inhibitor improves survival outcomes in patients with advanced BRAF-mutated melanoma, based on results of 2 phase 3 clinical trials presented at the 2014 European Society for Medical Oncology Congress.

Page 8 of 19

5
6
7
8
9
10
11